ClinicalTrials.gg
CompletedNCT03301948Updated Jan 14, 2019

Effects of a Single Day of Mixed Macronutrient Overfeeding on Energy Balance and Metabolic Responses

An interventional study of Overfeed and Energy Balance in Metabolic Disease and Appetitive Behavior, sponsored by Leeds Beckett University. Completed at 1 site in United Kingdom. Open to male participants aged 18 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-01-14.

Sponsored by Leeds Beckett University · Not applicable, Interventional, and Prevention

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled May 2017, registered Aug 2017).
Phase
Not applicable
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
18 Years to 35 Years
Sex
Male
01

Study summary

Healthy male participants are recruited to observe potentially deleterious changes in appetite regulation and metabolic control. Participants will be provided with an energy intake representative of their daily requirements on the first day of one trial and will be provided with an additional 50% energy intake on the first day of another trial. Outcome variables will be assessed during the second day of each trial in response to a fixed mixed macronutrient meal tolerance test.

Read the detailed description

All testing will take place within the Carnegie Research Institute, Leeds Beckett University. We will ask all the participants to visit on five occasions for the completion of a preliminary screening trial and two single-blind counterbalanced experimental trials which each require the participants to visit the laboratory on two consecutive days. The experimental trials will be separated by a minimum of one week.

Visit 1: Preliminary Screening:

Before an individual can take part in the experiment, they will need to undergo screening. Individuals will need to complete a Health Screen Questionnaire. Individuals will be excluded from the study if they are not currently in good health, have any condition that would alter their metabolism and/or have had significant medical problems in the past that may affect the outcomes of the study. Individuals will also be asked to be complete a Three-Factor Eating Questionnaire, to check that they are not restrained eaters, and an International Physical Activity Questionnaire (IPAQ) to ensure that all participants are either sedentary or moderately active. All individuals will be asked to confirm that they have been weight stable for at least six months before participating and that they are not currently dieting. Height, body mass and age will be collected to calculate the energy requirements for the main trials based on the Mifflin equation.

Visits 2, 3, 4 and 5: Experimental Trials:

The participants will be asked to record their food intakes and activity patterns during the three days prior to the first experimental test using a food and physical activity diary. They will then be instructed to repeat this diet and activity pattern prior to the second experimental trial. Participants will be required to arrive at the laboratory for all experimental trials after an overnight fast of at least 10 hours and having refrained from any strenuous activity for 48 hours, and alcohol and caffeine consumption in the previous 24 hours. Two hours before arriving at the laboratory on the day of the experimental trials, participants will be required to ingest 300 mL of water to standardise hydration levels for the trial.

During Day One of each experimental trial, participants will consume a porridge-based breakfast, soup- and pasta-based lunch, and rice-based evening meal under laboratory observation. The meals will contain macronutrient contents representative of current dietary recommendations of 50% carbohydrate, 15% protein and 35% fat. These meals have been selected to facilitate manipulation of the energy content, while matching the meals for appearance and palatability. During one trial, these meals will provide the calculated energy requirement for each individual based on the Mifflin equation and a physical activity factor of 1.4. The meals will be covertly manipulated to provide an additional 50% energy intake during the other trial. The provision of 150% of the estimated energy requirements for participants has been used in previous research for five day periods but will only be provided for a single day in the present study. Participants will be required to consume all of the diet during the standardised phase (i.e. either their daily energy requirements or the 50% overfeed) and will be blinded to the energy content of the trials. After the consumption of the evening meal (\~6pm), participants will have fulfilled the requirements for day one and will be asked not to consume any food prior to returning to the laboratory between 7am and 9am the next morning.

On Day Two of each experimental trial day, participants will arrive at the laboratory after an overnight fast and an Introcan Safety Cannula will be placed into a vein in the anticubital space for regular venous blood sampling. Blood samples will be collected in the fasted state and every 30 min after consumption of a standardised breakfast for a period of three hours. After the collection of the final blood sample, the cannula will be removed and participants will be provided with an ad libitum pasta meal (50% carbohydrate, 15% protein, 35% fat) for the assessment of energy intake. Participants will consume ad libitum meals in isolation to prevent any social influences and will be instructed to eat until 'satisfied'.

02

Conditions studied

  • Metabolic Disease
  • Appetitive Behavior
03

In context

Metabolic Diseases

763 studies on the registry are indexed under Metabolic Diseases; 192 are open to participants now.

This study's enrollment of 12 is below the median of 50 across 525 interventional studies indexed under Metabolic Diseases.

Browse Metabolic Diseases studies →

Lead sponsor

Leeds Beckett University is the lead sponsor of 10 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 35 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • weight stable
  • healthy

Exclusion criteria

Exclusion Criteria:

  • any personal history of cardiovascular or metabolic disease
  • smokers
  • currently dieting
  • taking any medication known to influence appetite or metabolic outcomes
  • highly active (IPAQ category 3)
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Overfeed

    Experimental trial where participants are provided with 50% higher energy intake than their estimated requirements on the first day of the trial.

    Other: Overfeed

  • Experimental
    Energy Balance

    Experimental trial where participants are provided with an energy intake equal to their estimated requirements on the first day of the trial.

    Other: Energy Balance

Interventions

  • OtherOverfeed

    Participants consume energy intakes that are 50% higher than their estimated requirements instead of consuming energy intakes equal to their estimated requirements

  • OtherEnergy Balance

    Participants consume energy intakes equal to their estimated requirements instead of consuming intakes that are 50% higher than their estimated requirements

06

What researchers measure

Primary outcomes

  1. Appetite perceptions assessed using 100mm visual analogue scales

    Appetite perceptions using 100mm visual analogue scales

    Time frame: 28 hours

  2. Ad libitum energy intake

    Ad libitum energy intake using an ad libitum pasta meal

    Time frame: 28 hours

  3. Plasma acylated ghrelin concentrations

    Measured using ELISA from venous blood samples

    Time frame: 28 hours

  4. Plasma peptide YY concentrations

    Measured using ELISA from venous blood samples

    Time frame: 28 hours

  5. Plasma GLP-1 concentrations

    Measured using ELISA from venous blood samples

    Time frame: 28 hours

Secondary outcomes

  1. Palatability perceptions assessed using 100mm visual analogue scales

    Palatability of the test meals assessed via 100mm visual analogue scales during the first day of each trial

    Time frame: 28 hours

  2. Blinding assessment

    To assess whether the blinding of dietary manipulation of the first day of each trial was successful. This will be assessed via an exit questionnaire which requires qualitative responses regarding any noticeable differences in the foods provided and what aspect of the food the participants thought had been manipulated during the trials.

    Time frame: One week

  3. Plasma insulin concentrations

    Measured using ELISA from venous blood samples

    Time frame: 28 hours

  4. Plasma glucose concentrations

    Measured using photometric analysis from venous blood samples

    Time frame: 28 hours

  5. Plasma triglyceride concentrations

    Measured using photometric analysis from venous blood samples

    Time frame: 28 hours

07

Study locations

1 site
  • Leeds Beckett University
    Leeds, LS6 3QS, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2017 to primary completion in Jan 2019, 20 months.

Of 182 non-industry interventional studies with no phase under Metabolic Diseases, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 44. This study's 20 months is close to that.

Counting every sponsor, half of 201 studies reached it within 22 months; a quarter within 10 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 8, 2017
First posted
Oct 4, 2017
StartActual
May 1, 2017
Primary completionActual
Jan 11, 2019
CompletionActual
Jan 11, 2019
Last update
Jan 14, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 14, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03301948
Lead sponsor
Leeds Beckett University
Responsible party
Sponsor
First posted
Oct 4, 2017
Start date
May 1, 2017
Primary completion
Jan 11, 2019
Completion
Jan 11, 2019
Last update
Jan 14, 2019

Study contacts

Kevin Deighton, PhD
principal investigator · Leeds Beckett University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion